Navigation Links
ChromaDex Announces Second Quarter 2008 Financial Results
Date:8/12/2008

IRVINE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the second quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the three months ended June 28, 2008.

As of June 28, 2008, cash, cash equivalents, and marketable securities totaled approximately $2.4 million. Balance sheet cash, cash equivalents and marketable securities includes all but approximately $1.1 million in proceeds from the final closings of the $4.6 million private placement the Company and its subsidiary just concluded.

"The second quarter of 2008 was significant for ChromaDex," said Frank Jaksch (http://www.chromadex.com/AboutCDX/fjaksch.html), CEO and co-founder of ChromaDex. "We successfully completed a reverse merger acquisition of Cody Resources, Inc. a publicly quoted company on the OTCBB. We did this in order to reap the benefits of public ownership including the ability to enhance our visibility with customers and prospective customers and access to potential new avenues for capital formation. Collectively, we believe this better positions ChromaDex to help us grow and expand to meet the significant and growing needs of customers. In the second half of 2008, we will be focused on expanding our range of products and services to the market."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during the second quarter of 2008 of $1,198,885 as compared to $997,087 for the same period in 2007. The net loss attributable to common stockholders for the three months ended June 28, 2008, was $621,676 as compared to $113,926 for the same period in 2007. The Company notes that as a result of the closing of the reverse merger acquisition of Cody Resources, Inc. on June 20, 2008, investors are cautioned that the Company's historical performance is not directly comparable.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to ability to market, produce and sell the referenced ingredients, risks relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Corporation and Subsidaries

Condensed Consolidated Statements of Operations (Unaudited)

Three Months ending

June 28, 2008 June 30, 2007

Sales $1,198,885 $997,087

Cost of goods sold 832,905 741,227

Gross profit 365,980 255,860

Operating expenses:

Selling 159,558 74,015

General and administrative 832,374 304,897

991,932 378,912

Operating loss (625,952) (123,052)

Nonoperating (income) expenses:

Interest expense 7,052 7,156

Interest income (11,550) (16,253)

Other 222 (830)

(4,276) (9,926)

Income taxes - 800

Net loss $(621,676) $(113,926)

Basic and Diluted loss per common share $(0.03) (0.01)

Basic and Diluted average common

shares outstanding 24,755,583 22,011,549

See Notes to Condensed Consolidated

Financial Statements.


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... BOSTON (PRWEB) , ... October 12, 2017 , ... ... name for two-dimensional representations of a complex biological network, a depiction of a ... a big mess,” said Dmitry Korkin, PhD, associate professor of computer science at ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
Breaking Biology News(10 mins):